15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering Sabra Healthcare REIT Inc, 4 rate it Buy or better, 7 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $19.00 to $25.00, so the covering firms are broadly aligned. The average target of $21.91 sits 2% below the current $22.26. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.17 next quarter toward $0.76 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Moderate Buy
Strong Buy00%
Buy433%
Hold758%
Sell18%
Strong Sell00%
Based on 12 analysts giving stock ratings to Sabra Healthcare REIT Inc.
As of Jul, 4 of 12 firms rate SBRA a Buy (7 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
SBRA EPS & revenue forecast
EPS · NEXT QUARTER
$0.17
Range $0.16 – $0.17 · 3 analysts · +0% YoY
Next period, 3 analysts expect Sabra Healthcare REIT Inc to earn $0.17 a share (range $0.16 – $0.17), versus $0.17 a year earlier. Full-year consensus is $0.67, growing to $0.76 the year after.
REVENUE · NEXT QUARTER
$225.2M
Range $217.5M – $233.9M · 3 analysts · +18% YoY
Revenue is expected to reach $225.2M (range $217.5M – $233.9M), +18.5% year-over-year. Full-year consensus is $898.1M, rising to $987.6M next year.
Top analysts covering Sabra Healthcare REIT Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SBRA.
#1
Michael Lewis
Truist Securities · Rank #178
Buy
$24.00+7.8% to target
Overall win rate
41%
+ Follow
#2
Aaron Hecht
JMP Securities · Rank #221
Buy
$22.00-1.2% to target
Overall win rate
42%
+ Follow
#3
Matthew J. Carletti
JMP Securities · Rank #239
Buy
$20.00-10.2% to target
Overall win rate
41%
+ Follow
#4
Nicholas Yulico
Scotiabank
Hold
$19.00-14.6% to target
Coverage
—
+ Follow
#5
John Kilichowski
Wells Fargo
Buy
$23.00+3.3% to target
Coverage
—
+ Follow
SBRA stock forecast FAQ
What is SBRA's average 12-month price target?+
The 11 analysts with a live target average $21.91 for Sabra Healthcare REIT Inc over the next 12 months, ranging from a $25.00 high to a $19.00 low.
Is SBRA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 12 analyst ratings, 4 are Buy or Strong Buy, 7 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for SBRA?+
The Street-high target is $25.00 (Citizens), and the Street-low is $19.00 (Citigroup). The average of all 11 active targets is $21.91.
How many Wall Street analysts cover SBRA?+
12 analysts have an active rating on Sabra Healthcare REIT Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering SBRA?+
Among analysts who currently cover SBRA, Michael Lewis of Truist Securities has the strongest overall Quantellect track record (Rank #178). Their current call is Buy with a $24.00 target.
What is Sabra Healthcare REIT Inc's projected EPS for next quarter?+
The consensus estimate is $0.17 per share (range $0.16 – $0.17) across 3 analysts. Full-year EPS is projected at $0.67, rising to $0.76 the following year.
How much revenue is Sabra Healthcare REIT Inc expected to report next quarter?+
Consensus revenue is $225.2M (range $217.5M – $233.9M). Full-year revenue is projected at $898.1M, growing to $987.6M next year.
Have analysts been upgrading or downgrading SBRA lately?+
As of Jul, 4 of 12 firms rate SBRA a Buy (7 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SBRA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Raymond James
